ピゾチフェン(15574-96-6)

ChemicalBook Optimization Suppliers
名前: J & K SCIENTIFIC LTD.  
電話番号: 010-82848833 400-666-7788
電子メール: jkinfo@jkchemical.com
名前: TCI (Shanghai) Development Co., Ltd.  
電話番号: 021-67121386
電子メール: Sales-CN@TCIchemicals.com
名前: Pure Chemistry Scientific Inc.  
電話番号: 001-857-928-2050 or 1-888-588-9418
電子メール: sales@chemreagents.com
名前: Adamas Reagent, Ltd.  
電話番号: 400-6009262 16621234537
電子メール: zhangsn@titansci.com
名前: LGM Pharma  
電話番号: 1-(800)-881-8210
電子メール: inquiries@lgmpharma.com
ピゾチフェン 製品概要
化学名:ピゾチフェン
英語化学名:Pizotifen
别名:Pizotylene;PIZOTHIFENUM;Pizotifenum;Pizotyline (base and/or unspecified salts);4-OXO-9,10-DIHYDRO-4H-BENZO(4,5) CYCLOHEPTO(1,2,B) THIOPHENE;PIZOTIFEN;4-(9,10-Dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thien-4-ylidene)-1-methylpiperidine;BC 105
CAS番号:15574-96-6
分子式:C19H21NS
分子量:295.44
EINECS:239-632-9
カテゴリ情報:Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Sandomigran, pizotyline;Pizotifen;Active Pharmaceutical Ingredients
Mol File:15574-96-6.mol
ピゾチフェン
ピゾチフェン 物理性質
融点 140-142°C
沸点 436.7±45.0 °C(Predicted)
比重(密度) 1.164±0.06 g/cm3(Predicted)
貯蔵温度 room temp
溶解性DMSO: ≥8mg/mL
酸解離定数(Pka)pKa 6.95 (Uncertain)
外見 powder
White to Off-White
Merck 14,7515
CAS データベース15574-96-6(CAS DataBase Reference)
NISTの化学物質情報Pizotyline(15574-96-6)
安全性情報
主な危険性 Xi,Xn
Rフレーズ 36/37/38-22-63
Sフレーズ 26-37/39-36/37
WGK Germany 3
RTECS 番号TM7165000
HSコード 2934.99.3000
MSDS Information
ピゾチフェン Usage And Synthesis
外観白色~ほとんど白色粉末~結晶
効能タンパク同化薬, 抗うつ薬, 抗片頭痛薬, セロトニン受容体拮抗薬
化学的特性White to Off-White Solid
OriginatorSandomigran ,Sandoz ,Italy ,1972
使用benzocycloheptane based drug
使用Serotonin antagonist structurally related to Cyproheptadine. Antimigraine; appetite stimulant.
適応症Pizotifen, a potent antihistamine and antiserotonin agent usually prescribed for migraine prophylaxis, has had reported success in patients with polycythemia vera.
定義ChEBI: A benzocycloheptathiophene that is 9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thiophene 4-ylidene)-1-methylpiperidine which is joined from the 4 position to the 4 position of an N-methylpiperidine moiety b a double bond. It is a sedating antihistamine, with strong serotonin antagonist and weak antimuscarinic activity. It is generally used as the malate salt for the treatment of migraine and the prevention of headache attacks during cluster periods.
Manufacturing Process(A) Preparation of Thenylidene-(2)-Phthalide: 24.2 g of thienyl-(2)-acetic acid, 52.0 g of phthalic acid anhydride, 4.0 g of anhydrous sodium acetate and 125 ml of 1-methylpyrrolidone-(2) are heated while stirring in an open flask for 3 hours to 205° to 208°C, while nitrogen is passed through. It is then cooled and the viscous reaction mixture poured into 1 liter of water. The precipitated substance is filtered off, washed with water and then dissolved in 200 ml of chloroform. After filtering off some undissolved substance, shaking is effected twice with 100 ml of 2 N sodium carbonate solution and then with water, drying is then carried out over sodium sulfate and the volume is reduced by evaporation. The crude phthalide is repeatedly recrystallized from ethanol, while treating with animal charcoal. It melts at 114° to 115°C.
(B) Preparation of o-[2-Thienyl-(2')-Ethyl]Benzoic Acid: 24.0 g of thenylidene(2)-phthalide, 8.8 g of red pulverized phosphorus, 240 ml of hydrochloric acid (d = 1.7) and 240 ml of glacial acetic acid are heated to boiling under nitrogen and while stirring vigorously. 70 ml toluene are then added and 6.0 g of red phosphorus added in small portions over a period of 1 hour. It is then poured into 3 liters of ice water, stirred with 300 ml of chloroform and the phosphorus removed by filtration.
The chloroform phase is then removed, the aqueous phase extracted twice more with 200 ml of chloroform and the united extracts shaken out 4 times,each time with 200 ml of 2 N sodium hydroxide solution. The alkaline solution is then rendered acid to Congo red reagent, using hydrochloric acid and extracted 3 times with chloroform. After drying over sodium sulfate and evaporating the solvent, the residue is chromatographed on aluminum oxide (Activity Stage V). The substance eluted with benzene and benzene/chloroform (1:1) is recrystallized from chloroform/hexane (1:1); MP 107° to 109°C.
(C) Preparation of 9,10-Dihydro-4H-Benzo[4,5]Cyclohepta[1,2-b]Thiophen(4)-One: 200 ml of 85% phosphoric acid and 112 g of phosphorus pentoxide are heated to 135°C. 7.0 g of o-[2-thienyl-(2')-ethyl]benzoic acid are then introduced while stirring thoroughly over a period of 30 min. Stirring is then continued for another hour at 135°C and the reaction mixture is then stirred into 1 liter of ice water. Extraction is then effected 3 times, using 250 ml ether portions, the ethereal extract is washed with 2 N sodium carbonate solution, dried over sodium sulfate and reduced in volume by evaporation. The residue is boiled up with 55 ml of ethanol, the solution freed of resin by decanting and then stirred at room temperature for 6 hours with animal charcoal. It is then filtered off, reduced in volume in a vacuum and the residue distilled. BP 120° to 124°C/0.005 mm, nD24.5 = 1.6559.
(D) Preparation of 4-[1'-Methyl-Piperidyl-(4')]-9,10-Dihydro-4HBenzo[4,5]Cyclohepta[1,2b]Thiophen-(4)-ol: 0.94 g of magnesium filings which have been activated with iodine are covered with a layer of absolute tetrahydrofuran and etched with a few drops of ethylene bromide. A solution of 5.0 g of 1-methyl-4-chloropiperidine in 5 ml of tetrahydrofuran is then added dropwise and boiling then effected for a further hour under reflux. After cooling to room temperature, the solution of 4.5 g of 9,10-dihydro-4Hbenzo[4,5]cyclohepta[1,2-b]thiophen-(4)-one in 5 ml of tetrahydrofuran is added dropwise.
Stirring is carried out first for 3 hours at room temperature and then for 2 hours at boiling temperature, it is then cooled and poured into 300 ml of icecold 20% ammonium chloride solution. It is then shaken out with methylene chloride, the methylene chloride solution washed with water and shaken 3 times with 30 ml portions of aqueous 2 N tartaric acid solution. The tartaric acid extract is rendered alkaline while cooling thoroughly and then extracted twice with methylene chloride. After washing with water, drying over potassium carbonate and reducing in volume by evaporation, the residue is recrystallized from ethanol. MP 197° to 199°C.
(E) Preparation of 4-[1'-Methyl-Piperidylidene-(4')]-9,10-Dihydro-4HBenzo[4,5]Cyclohepta[1,2-b]Thiophene Hydrochloride: 2 g of 4-[1'-methylpiperidyl-(4')]-9,10-dihydro4H-benzo[4,5]cyclohepta[1,2-b]thiophen-(4)-ol, 60 ml of glacial acetic acid and 20 ml of concentrated hydrochloric acid are boiled for 30 minutes under reflux. After evaporating in a vacuum, the residue is triturated with 3 ml of acetone, the precipitated hydrochloride is then filtered off and it is recrystallized from isopropanol/ether. MP 261° to 263°C (decomposition).
brand nameSandomigran (Novartis).
Therapeutic FunctionMigraine therapy
Biochem/physiol ActionsPizotifen is a serotonin antagonist acting mainly at the 5-HT1, 5-HT2A and 5HT2C receptors with some antihistamine activity. It is used for the prevention of vascular headache including migraine and cluster headache.
臨床応用Prophylactic treatment of vascular headaches including migraine
薬物相互作用Potentially hazardous interactions with other drugs
Adrenergic neurone blockers: pizotifen antagonises hypotensive effect.
代謝Pizotifen undergoes extensive metabolism.
Over half of a dose is excreted in the urine, chiefly as metabolites; a significant proportion is excreted in the faeces.
Tags:15574-96-6